Greenwich LifeSciences Inc 2026年季度报告

Form 10-Q (Mark One) ☒QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-39555 GREENWICH LIFESCIENCES, INC.(Exact Name of registrant as specified in its charter) (832) 819-3232(Registrant’s telephone number, including area code) Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Actduring the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, everyInteractive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during thepreceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reportingcompany☒Emerging growthcompany☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of May 26, 2026, the issuer had 14,678,208 shares of Common Stock issued and outstanding. GREENWICH LIFESCIENCES, INC. Table of Contents PagePART IFINANCIAL INFORMATION3Item 1.Financial Statements (unaudited)3Balance Sheets as of March 31, 2026 and December 31, 2025 (Unaudited)3Statements of Operations for the Three Months Ended March 31, 2026 and 2025 (Unaudited)4Statements of Stockholders’ Equity for the Three Months Ended March 31, 2026 and 2025 (Unaudited)5Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025 (Unaudited)6Notes to Financial Statements (Unaudited)7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations10Item 3.Quantitative and Qualitative Disclosures About Market Risk13Item 4.Controls and Procedures13PART IIOTHER INFORMATION14Item 1.Legal Proceedings14Item 1A.Risk Factors14Item 2.Unregistered Sales of Equity Securities and Use of Proceeds14Item 3.Defaults Upon Senior Securities14Item 4.Mine Safety Disclosures14Item 5.Other Information14Item 6:Exhibits15SIGNATURES16-2- PART I. FINANCIAL INFORMATION GREENWICH LIFESCIENCES, INC.BALANCE SHEETSAS OF MARCH 31, 2026 AND DECEMBER 31, 2025 (UNAUDITED) GREENWICH LIFESCIENCES, INC.STATEMENTS OF OPERATIONSFOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025 (UNAUDITED) GREENWICH LIFESCIENCES, INC.STATEMENTS OF STOCKHOLDERS’ EQUITYFOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025 (UNAUDITED) GREENWICH LIFESCIENCES, INC.STATEMENTS OF CASH FLOWSFOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025 (UNAUDITED) Three Months Ended March 31,20262025Operating activities:Net loss$(5,657,137)$(2,744,780)Adjustments required to reconcile net loss to net cash used in operating activities:Amortization—903Stock-based compensation1,544,2141,544,214Changes in operating assets and liabilities:Accounts payable(365,461)(643,237)Unreimbursed expenses (accrued)(224,114)8,446Net cash used in operating activities(4,702,498)(1,834,454)Financing activities:Sale of common stock via ATM program, net of costs9,029,912492,423Net cash provided by financing activities9,029,912492,423Net increase (decrease) in cash4,327,414(1,342,031)Cash, beginning of period6,178,0214,091,990Cash, end of period$10,505,435$2,749,959 GREENWICH LIFESCIENCES, INC.NOTES TO FINANCIAL STATEMENTS(UNAUDITED) 1. Organization and Description of the Business Greenwich LifeSciences, Inc. (the “Company”) was incorporated in the state of Delaware in 2006 under the name Norwell, Inc. InMarch 2018, Norwell, Inc. changed its name to Greenwich LifeSciences, Inc. In February 2023, Greenwich LifeSciences EuropeLimited was incorporated as a wholly owned subsidiary in Ireland. The Company is developing a breast cancer immunotherapyfocused on preventing the recurrence of breast cancer following surgery. 2. Going Concern The Company has prepared its financial statements on a going concern basis, which assumes that the Company will realize its assetsand satisfy its liabilities in the normal cour